Infantile Hemangioma
Conditions
Interventions
Early stage Proliferation:0.5% Timolol Maleate
Late stage Proliferation:0.5% Timolol Maleate
Sponsors
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School Of Medicine
Eligibility
Sex/Gender
All
Age
No minimum to 1 Years
Inclusion criteria
Inclusion criteria: 1. Patients who were diagnosed with Infantile Hemangioma according to ISSVA diagnostic criteria; 2. Patients with superficial Infantile Hemangiomas presented to Shanghai Ninth People's Hospital during the time period of July to December, 2018. (Patients under 2 months' age were included in early stage proliferation group, patients aged over 2 months and under 1 year old were included in late stage proliferation group.) 3. Untreated lesion; 4. Lesions without ulceration, atrophy, bleeding, etc. 5. Willing to cooperate with treatment.
Exclusion criteria
Exclusion criteria: 1. Those with severe immune deficiency or congenital diseases; 2. Patients participating in other clinical trials or recieving other treatments; 3. Patients who have beta blocker drug allergies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| VAS; | — |
Countries
China
Contacts
Public ContactXiaoxi Lin
Shanghai Ninth People's Hospital, Shanghai Jiaotong University School Of Medicine
Outcome results
None listed